Explore

Trendline Trendline
Johnson Johnson Expands U.S. Roll-Out of TECNIS PureSee IOL for Cataract Patients

Johnson Johnson Expands U.S. Roll-Out of TECNIS PureSee IOL for Cataract Patients

Johnson Johnson Expands U.S. Roll-Out of TECNIS PureSee IOL for Cataract Patients
Trendline Trendline
ZEISS Announces Successful Early Implantations of AT LUCIA Toric 721P Intraocular Lens

ZEISS Announces Successful Early Implantations of AT LUCIA Toric 721P Intraocular Lens

ZEISS Announces Successful Early Implantations of AT LUCIA Toric 721P Intraocular Lens
Trendline Trendline
Vertex Pharmaceuticals Presents New Data on CASGEVY for Pediatric Sickle Cell and Beta Thalassemia

Vertex Pharmaceuticals Presents New Data on CASGEVY for Pediatric Sickle Cell and Beta Thalassemia

Vertex Pharmaceuticals Presents New Data on CASGEVY for Pediatric Sickle Cell and Beta Thalassemia
Rapid Read Rapid Read
Bridge to Life to Present Organ Preservation Innovations at American Transplant Congress

Bridge to Life to Present Organ Preservation Innovations at American Transplant Congress

Bridge to Life Ltd., a company specializing in organ preservation and perfusion technologies, is set to present several oral presentations at the 2026 Annual Meeting of the American Transplant Congress (ATC) in Boston, Massachusetts. The event, scheduled from June 20-24, 2026, will feature discussions on Hypothermic Oxygenated Perfusion (HOPE) technology, which is used in human uterus and small intestine transplants. The presentations will include a plenary session comparing HOPE with normothermic oxygenated perfusion. Key speakers from the Cleveland Clinic and other institutions will discuss the latest advancements in organ preservation, including the use of donor serum FMN to predict outcomes after liver transplantation. The symposium aims to connect clinical evidence with real-world implementation, focusing on the economic and operational realities of adopting perfusion technologies at scale.
Trendline Trendline
Smith+Nephew Launches CORI XT Handheld Robotics Platform for Knee and Shoulder Arthroplasty

Smith+Nephew Launches CORI XT Handheld Robotics Platform for Knee and Shoulder Arthroplasty

Smith+Nephew Launches CORI XT Handheld Robotics Platform for Knee and Shoulder Arthroplasty
Trendline Trendline
Onkos Surgical Gains FDA Clearance for NanoCept Technology on Titanium Implants

Onkos Surgical Gains FDA Clearance for NanoCept Technology on Titanium Implants

Onkos Surgical Gains FDA Clearance for NanoCept Technology on Titanium Implants
Rapid Read Rapid Read
Bridge to Life Highlights Organ Preservation Advances at American Transplant Congress

Bridge to Life Highlights Organ Preservation Advances at American Transplant Congress

Bridge to Life Ltd., a leader in organ preservation technologies, announced its participation in the 2026 Annual Meeting of the American Transplant Congress (ATC) in Boston. The company will present several oral abstracts, including a plenary session on Hypothermic Oxygenated Perfusion (HOPE) for human uterus and small intestine transplants. These presentations will explore the benefits of HOPE compared to normothermic oxygenated perfusion, highlighting advancements in organ preservation and viability assessment.
Rapid Read Rapid Read
Onkos Surgical Gains FDA Clearance for NanoCept Technology on Titanium Implants

Onkos Surgical Gains FDA Clearance for NanoCept Technology on Titanium Implants

Onkos Surgical has received clearance from the U.S. Food and Drug Administration (FDA) for the application of its NanoCept Antibacterial Technology on titanium implants within the ELEOS Limb Salvage System. This marks the second 510(k) clearance for the technology since its original De Novo authorization. The NanoCept-coated implants are designed to support oncology and revision patients who are at an elevated risk for bacterial contamination. By enabling the application of NanoCept to titanium, Onkos Surgical expands access to antibacterial implant technology across a wider portion of the ELEOS system. This development provides surgeons with an integrated option to address bacterial contamination on implant surfaces prior to implantation.
Rapid Read Rapid Read
Sonex Health's Study Validates Ultrasound-Guided Carpal Tunnel Release

Sonex Health's Study Validates Ultrasound-Guided Carpal Tunnel Release

Sonex Health has announced results from the largest-ever U.S. study on ultrasound-guided carpal tunnel release (UGCTR), demonstrating its safety and efficacy. The study, published in the Journal of Hand Surgery Global Online, involved 887 patients and 1,082 hands treated across 22 sites. The findings show rapid improvement in symptoms and high patient satisfaction, with a median recovery time of three days. UGCTR allows for simultaneous treatment of both hands and is performed using local anesthesia, reducing recovery time and healthcare costs. The study aims to compare UGCTR with other procedural approaches like endoscopic and open carpal tunnel release.
Rapid Read Rapid Read
PainTEQ Launches Clinical Study for Innovative Sacroiliac Joint Procedure

PainTEQ Launches Clinical Study for Innovative Sacroiliac Joint Procedure

PainTEQ has announced the enrollment of the first patient in the TRAQTION Study, a clinical trial evaluating the outcomes of posterior sacroiliac joint procedures using the TRAQ™ allograft. The study aims to enroll up to 100 patients across 10 U.S. sites, following them for 24 months to assess patient-reported outcomes, safety, and healthcare utilization. The TRAQ™ procedure involves a cortical-piercing trajectory through the sacrum and ilium, building on existing sacroiliac joint procedures to improve patient outcomes.
Trendline Trendline
Exosome Therapy Emerges as a Promising Solution for Hair Growth

Exosome Therapy Emerges as a Promising Solution for Hair Growth

Exosome Therapy Emerges as a Promising Solution for Hair Growth
Rapid Read Rapid Read
Aignostics and PanCAN Collaborate to Enhance Pancreatic Cancer Research with AI Technology

Aignostics and PanCAN Collaborate to Enhance Pancreatic Cancer Research with AI Technology

Aignostics, an artificial intelligence company, has announced a partnership with the Pancreatic Cancer Action Network (PanCAN) to enhance pancreatic cancer research. This collaboration will utilize Aignostics' AI technology to analyze pathology images within PanCAN's SPARK data platform. The AI-powered application, Atlas H&E-TME, will provide comprehensive spatial profiling, generating over 4,500 quantitative readouts per image. These outputs will be accessible to academic researchers at no cost and available for commercial licensing by life sciences companies. The partnership aims to improve understanding of pancreatic cancer biology and patient outcomes by integrating spatial information into PanCAN's multimodal dataset.